Business Context and Reporting Period
This Form 8-K Current Report from Relmada Therapeutics, Inc. covers the 2015 Annual Meeting of Stockholders held on December 30, 2015. The filing details the voting results for director elections and the ratification of the independent registered public accounting firm.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance events.
Material Changes
There are no material financial changes reported in this filing. The primary event is the completion of the 2015 Annual Meeting, where 5,111,604 shares (45.61% of eligible common stock) were present in person or by proxy.
Guidance, Outlook, and Management Commentary
- Director Elections (Proposal 1): Shreeram Agharkar and Maged Shenouda were elected as Class I directors for a three-year term. Both candidates received over 4.3 million "For" votes with zero abstentions.
- Accounting Firm Ratification (Proposal 2): GBH CPAs, PC was ratified as the independent registered public accounting firm for the fiscal year ending June 30, 2016, with 4,997,383 votes "For" and 104,581 votes "Against."
- Press Release: The Company issued a press release on December 30, 2015, confirming the election results, which is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for additional context on the director elections.
- Confirm the upcoming fiscal year end date of June 30, 2016, for future financial reporting expectations.
- Note that this filing contains no financial statements; refer to the most recent 10-K or 10-Q for financial health metrics.